A randomized prospective assessor-blind evaluation of luteinizing hormone dosage and in vitro fertilization outcome

Fertility and Sterility

Volumn 75, Issue 2, 2001, Pages 324-331

  Gordon, Uma Deve ^a   Harrison, Robert F ^b   Fawzy, Medhat ^b   Hennelly, Benny ^b   Gordon, Andrew C ^c  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

^b ROTUNDA HOSPITAL   (Ireland)

^c Bath Assisted Conception Unit   (United Kingdom)

Author keywords

IVF; LH dosage; Outcome

Indexed keywords

BUSERELIN ACETATE; FOLLITROPIN; GONADOTROPIN; HUMAN MENOPAUSAL GONADOTROPIN; LUTEINIZING HORMONE; RECOMBINANT FOLLITROPIN; UROFOLLITROPIN;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; FERTILIZATION IN VITRO; HUMAN; PREGNANCY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; TREATMENT OUTCOME;

ADULT; CELL COUNT; CHORIONIC GONADOTROPIN; DOSE-RESPONSE RELATIONSHIP, DRUG; EMBRYO IMPLANTATION; ESTRADIOL; FEMALE; FERTILIZATION IN VITRO; FOLLICLE STIMULATING HORMONE; HUMANS; LUTEINIZING HORMONE; OOCYTES; OVARIAN FOLLICLE; OVULATION INDUCTION; PREGNANCY; PROSPECTIVE STUDIES;

EID: 0035140105     PISSN: 00150282     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0015-0282(00)01701-5     Document Type: Article

References (52)

1. Oestrogen biosynthesis in the ovaries and testis
2. Biological basis of follicle growth
3. Re-evaluation of the roles of luteinizing hormone and follicle-stimulating hormone in the ovulatory process
4. Human recombinant follicle stimulating hormone induces growth of preovulatory follicles without concomitant increase in androgen and oestrogen biosynthesis in a woman with isolated gonadotropin deficiency
5. Influence of serum luteinising hormone concentrations on ovulation, conception, and early pregnancy loss in polycystic ovary syndrome
6. Hypersecretion of luteinizing hormone and ovarian steroids in women with recurrent early miscarriage
7. Ovulatory response rate with human menopausal gonadotropins of varying FSH:LH ratios
8. A randomized comparative study of purified follicle stimulating hormone and human menopausal gonadotropin after pituitary desensitization with buserelin for superovulation and in vitro fertilization
9. Use of follicle stimulating hormone alone (urofollitropin) to stimulate the ovaries for assisted conception after pituitary desensitization
10. Randomized controlled trial of follicle stimulating hormone versus human menopausal gonadotropin in in-vitro fertilization
11. Comparison of efficacy of high dose pure follicle stimulating hormone versus human menopausal gonadotropins for in vitro fertilization
12. Composition of commercial gonadotropin preparations extracted from human post-menopausal urine; characterization of non-gonadotropin proteins
13. Expression of biologically active human follitropin in Chinese hamster ovary cells
14. Comparative in vitro and in vivo studies on the biological characteristics of recombinant human follicle stimulating hormone
15. Recombinant versus follicle stimulating hormone for ovarian stimulation in assisted reproduction
16. Variation in the biological and biochemical characteristics of human menopausal gonadotropin
17. A randomized prospective study of early follicular or midluteal initiation of long protocol gonadotropin-releasing hormone in an in vitro fertilization program
18. An Irish out-patient based in-vitro fertilisation service
19. Early follicular rise of serum progesterone concentration in response to a flare up effect of gonadotropin-releasing hormone agonist impairs follicular recruitment for in-vitro fertilization
20. Controlled ovarian stimulation using highly purified FSH results in a lower serum estradiol profile in the follicular phase as compared with hMG
21. Results of ovulation induction using human menopausal gonadotropins or purified follicle-stimulating hormone in hypogonadotropic hypogonadism patients
22. The role of luteinizing hormone in human follicle development and oocyte fertility; evidence from in-vitro fertilization in a woman with long-standing hypogonadotropic hypogonadism and using recombinant human follicle stimulating hormone
23. Randomized trial of three luteinizing hormone-releasing hormone analogues used for ovarian stimulation in an in vitro fertilization program
24. Comparison of urinary human follicle stimulating hormone and human menopausal gonadotropins for ovarian stimulation in an in vitro fertilization program
25. Follicle stimulating hormone versus human menopausal gonadotropin for in vitro fertilization; results of a meta-analysis
26. A prospective, randomized clinical trial comparing 150 IU recombinant follicle stimulating hormone (Puregon®) and 225 IU highly purified urinary follicle stimulating hormone (Metrodin-HP®) in a fixed-dose regimen in women undergoing ovarian stimulation
27. Amounts and composition of LH and HCG in two similar commercial hMG preparations
28. Structure-function relationship of recombinant follicle-stimulating hormone (Puregon)
29. Influence of the assay method used on the selection of the most active forms of FSH from the human pituitary
30. Clinical profiling of recombinant follicle stimulating hormone (rFSH; Puregon); relationship between serum FSH and efficacy
31. In vitro biopotency and glycoform distribution of recombinant human follicle stimulating hormone (Org 32489), Metrodin and Metrodin-HP
32. Follicle-stimulating isoforms; characterisation and physiological relevance
33. Recombinant human luteinising hormone (LH) to support recombinant human follicle-stimulating hormone (FSH)-induced follicular development in LH- and FSH-deficient anovulatory women; a dose-finding study
34. Developmental potential of embryos produced by in vitro fertilization from gonadotropin-releasing hormone antagonist treated macaques stimulated with recombinant human follicle stimulating hormone alone or in combination with luteinizing hormone
35. Recombinant human luteinising hormone; an effective new gonadotropin preparation
36. Very high serum estradiol levels are not detrimental to clinical outcome of in vitro fertilization
37. Assessment of the role of serum luteinizing hormone and estradiol response to follicle stimulating hormone on in vitro fertilization outcome
38. The presence of gonadotropin receptors in non-pregnant uterus, human placenta, foetal membranes and decidua
39. Artificial agonadism and hormone replacement for oocyte donation
40. Controlled preparation of the endometrium with exogenous oestradiol and progesterone in women having functioning ovaries
41. Is endometrial development in the peri-implantation period influenced by high concentrations of luteinizing hormone in the follicular phase?
42. A prospective, randomized comparison of ovulation induction using highly purified follicle-stimulating hormone alone and with recombinant human luteinizing hormone in in-vitro fertilization
43. Follicle-stimulating hormone or human menopausal gonadotropin for ovarian stimulation in in vitro fertilization cycles; a meta-analysis
44. A double-blind, randomized, dose-finding study to assess the efficacy of the GnRH-antagonist Ganirelix (Org 37462) to prevent premature luteinizing hormone surges in women undergoing controlled ovarian hyperstimulation with recombinant follicle stimulating hormone
45. Reduced in-vitro fertilisation of human oocytes from patients with raised basal luteinising hormone levels during the follicular phase
46. Hypersecretion of luteinising hormone, infertility, and miscarriage
47. Do raised serum luteinising hormone levels during stimulation for in-vitro fertilisation predict outcome?
48. The relationship of early follicular phase serum LH and pregnancy rates in women with regular menses
49. The effect of serum follicular phase luteinizing hormone concentrations in habitual abortion. Correlation with the results of paternal leukocyte immunization